Back to today’s briefing

Story perspectives

Breakthrough Breath Test for Cystic Fibrosis Secures $2.3M

4/23/2025

31 3

Summary

Story summary

Owlstone Medical has secured a significant USD $2.3 million investment from the Cystic Fibrosis Foundation to innovate a breath test that detects Pseudomonas aeruginosa in cystic fibrosis patients. This groundbreaking test promises diagnostic accuracy on par with traditional sputum cultures, paving the way for earlier infection detection and improved management of this life-altering condition affecting over 105,000 people worldwide.

1 of 1

Story summary

Owlstone Medical has secured a significant USD $2.3 million investment from the Cystic Fibrosis Foundation to innovate a breath test that detects Pseudomonas aeruginosa in cystic fibrosis patients. This groundbreaking test promises diagnostic accuracy on par with traditional sputum cultures, paving the way for earlier infection detection and improved management of this life-altering condition affecting over 105,000 people worldwide.